{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:14:37Z","timestamp":1777490077723,"version":"3.51.4"},"reference-count":42,"publisher":"BMJ","issue":"4","funder":[{"name":"Beijing Chao-Yang Hospital Golden Seeds Fundation","award":["CYJZ202108"],"award-info":[{"award-number":["CYJZ202108"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2023,1,3]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In recent years, patients with programmed cell death-Ligand 1 (PD-L1)-positive oesophageal squamous cell carcinoma (OSCC) have been able to benefit from immunotherapy. However, method for improving the treatment efficacy of PD-L1-positive patients is a problem that needs further consideration. Studies on the relationship between human epidermal growth factor receptor 2 (HER2) and PD-L1 expression have recently been reported in certain cancers, but the relationship between PD-L1 and HER2 expression in OSCC is still unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 263 patients with OSCC were included in the study. PD-L1 protein expression and HER2 protein expression were analysed by immunohistochemistry (IHC), and fluorescence in situ hybridisation (FISH) was performed to assess\n                      <jats:italic>HER2<\/jats:italic>\n                      gene amplification. The significance of differences between HER2 status, PD-L1 status and clinicopathological parameters was assessed. The relationship between PD-L1 status and HER2 status was examined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 263 OSCC cases, the PD-L1-positive expression rates were 39.2% and 77.2% in OSCC for Tumour Proportion Score (TPS) and Combined Positive Score (CPS), respectively, and PD-L1 expression was associated with the degree of tumour differentiation. The HER2 expression was positive in 24% (63\/263) of cases based on IHC and FISH. HER2 expression was not significantly associated with clinicopathological characteristics. PD-L1 TPS expression and CPS expression were significantly positively correlated with HER2 expression in OSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PD-L1 expression was significantly positively correlated with HER2 expression in OSCC. The results provide valuable insight for the future application of HER2-targeted therapy combined with immunotherapy in OSCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jcp-2022-208665","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T04:28:05Z","timestamp":1674016085000},"page":"233-238","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Expression and correlation of PD-L1 and HER2 in oesophageal squamous cell carcinoma"],"prefix":"10.1136","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-296X","authenticated-orcid":false,"given":"Lulu","family":"Rong","sequence":"first","affiliation":[{"name":"Department of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongying","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mulan","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"2025120618001954000_77.4.233.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025120618001954000_77.4.233.2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41392-020-00323-3","article-title":"Advances in targeted therapy for esophageal cancer","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2025120618001954000_77.4.233.3","doi-asserted-by":"publisher","DOI":"10.3892\/or.2015.4435"},{"key":"2025120618001954000_77.4.233.4","doi-asserted-by":"publisher","DOI":"10.1586\/17474124.2016.1140036"},{"key":"2025120618001954000_77.4.233.5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1245\/s10434-016-5376-z","article-title":"Expression of PD-L1 and HLA class I in esophageal squamous cell carcinoma: prognostic factors for patient outcome","volume":"23","author":"Ito","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2025120618001954000_77.4.233.6","doi-asserted-by":"crossref","first-page":"30772","DOI":"10.18632\/oncotarget.8956","article-title":"Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"2025120618001954000_77.4.233.7","doi-asserted-by":"crossref","first-page":"7913","DOI":"10.18632\/oncotarget.6861","article-title":"The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"2025120618001954000_77.4.233.8","doi-asserted-by":"crossref","unstructured":"Lee HK , Kwon MJ , Ra YJ , et al . Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma. Diagn Pathol 2020;15.doi:10.1186\/s13000-020-01045-4","DOI":"10.1186\/s13000-020-01045-4"},{"key":"2025120618001954000_77.4.233.9","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.21037\/tcr.2020.03.22","article-title":"High programmed death-ligand 1 expression is a poor prognostic indicator for esophageal squamous cell carcinoma and is correlated with two-field lymph node metastasis","volume":"9","author":"Liang","year":"2020","journal-title":"Transl Cancer Res"},{"key":"2025120618001954000_77.4.233.10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.humpath.2018.09.014","article-title":"PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma","volume":"84","author":"Guo","year":"2019","journal-title":"Hum Pathol"},{"key":"2025120618001954000_77.4.233.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888"},{"key":"2025120618001954000_77.4.233.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4"},{"key":"2025120618001954000_77.4.233.13","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25613"},{"key":"2025120618001954000_77.4.233.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-019-0352-z"},{"key":"2025120618001954000_77.4.233.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30169-8"},{"key":"2025120618001954000_77.4.233.16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605772"},{"key":"2025120618001954000_77.4.233.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103339","article-title":"Prevalence of HER2 overexpression and amplification in squamous cell carcinoma of the esophagus: a systematic review and meta-analysis","volume":"161","author":"Egebjerg","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025120618001954000_77.4.233.18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-019-0798-2","article-title":"Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives","volume":"12","author":"Krasniqi","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2025120618001954000_77.4.233.19","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3390\/jcm9051265","article-title":"Differential expression and clinicopathological significance of HER2, indoleamine 2,3-dioxygenase and PD-L1 in urothelial carcinoma of the bladder","volume":"9","author":"Kim","year":"2020","journal-title":"JCM"},{"key":"2025120618001954000_77.4.233.20","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/cam4.1502","article-title":"Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status","volume":"7","author":"Wang","year":"2018","journal-title":"Cancer Med"},{"key":"2025120618001954000_77.4.233.21","first-page":"304","article-title":"Cancer of the esophagus and esophagogastric junction-major changes in the American joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Rice","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2025120618001954000_77.4.233.22","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41379-020-0644-7","article-title":"Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)","volume":"34","author":"de Ruiter","year":"2021","journal-title":"Mod Pathol"},{"key":"2025120618001954000_77.4.233.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.4836"},{"key":"2025120618001954000_77.4.233.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738"},{"key":"2025120618001954000_77.4.233.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02318"},{"key":"2025120618001954000_77.4.233.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30328-6"},{"key":"2025120618001954000_77.4.233.27","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.3892\/ol.2016.4301","article-title":"Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer","volume":"11","author":"Xu","year":"2016","journal-title":"Oncol Lett"},{"key":"2025120618001954000_77.4.233.28","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-016-0794-0"},{"key":"2025120618001954000_77.4.233.29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cca.2017.02.005","article-title":"PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients","volume":"469","author":"Xia","year":"2017","journal-title":"Clin Chim Acta"},{"key":"2025120618001954000_77.4.233.30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.21037\/jgo-20-568","article-title":"Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis","volume":"12","author":"Qiu","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"2025120618001954000_77.4.233.31","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1097\/CM9.0000000000001642","article-title":"Programmed cell death ligand 1 expression in esophageal squamous cell carcinoma: a comparative analysis of three different assays","volume":"134","author":"Guo","year":"2021","journal-title":"Chin Med J"},{"key":"2025120618001954000_77.4.233.32","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/PO.20.00412","article-title":"Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review","volume":"5","author":"Prince","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2025120618001954000_77.4.233.33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/cas.15198","article-title":"PD\u2010L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma","volume":"113","author":"Okadome","year":"2022","journal-title":"Cancer Sci"},{"key":"2025120618001954000_77.4.233.34","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.tranon.2018.08.005","article-title":"Chemotherapeutic treatments increase PD-L1 expression in esophageal squamous cell carcinoma through EGFR\/ERK activation","volume":"11","author":"Ng","year":"2018","journal-title":"Transl Oncol"},{"key":"2025120618001954000_77.4.233.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2006.00570.x"},{"key":"2025120618001954000_77.4.233.36","first-page":"4975","article-title":"Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma","volume":"33","author":"K\u00f6nig","year":"2013","journal-title":"Anticancer Res"},{"key":"2025120618001954000_77.4.233.37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602499"},{"key":"2025120618001954000_77.4.233.38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-6"},{"key":"2025120618001954000_77.4.233.39","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-569"},{"key":"2025120618001954000_77.4.233.40","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-9850-y"},{"key":"2025120618001954000_77.4.233.41","doi-asserted-by":"crossref","DOI":"10.1186\/s13000-020-00950-y","article-title":"HER2 expression and relevant clinicopathological features in esophageal squamous cell carcinoma in a Chinese population","volume":"15","author":"Rong","year":"2020","journal-title":"Diagn Pathol"},{"key":"2025120618001954000_77.4.233.42","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(20)30326-0","article-title":"Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial","volume":"21","author":"Catenacci","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2022-208665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T02:00:30Z","timestamp":1765072830000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2022-208665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,20]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/jcp-2022-208665"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2022-208665","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]}}}